Latest Wearables News

Epiminder has enrolled the 75th patient in its DETECT study, meeting its September target as the US site network expands to 21 centres. The company expects to reach 100 enrolments in November and remains focused on completing the 210-patient study by the end of the first half of calendar 2027.

Simble Solutions’ NanoSensor has detected UV-A, UV-B, UV-C and visible wavelengths in initial laboratory testing, moving the platform into formal benchmarking. The result is an encouraging technical step, but commercial progress still depends on performance data, prototypes and customer validation.

Simble Solutions has demonstrated its NanoSensor platform detecting volatile organic compounds at molecular sensitivity, marking a key step towards commercial gas sensing applications integrated with its digital platforms.

Nanoveu's EMASS division has been granted a US patent for a silicon accelerator that dramatically speeds up AI object detection, underpinning its next-gen ECS-DoT chip now in production at TSMC.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Spacetalk Ltd reported a 17% revenue decline in FY26 amid a strategic reset, but mobile revenue grew 16% as the company pivots to a software-led family safety platform supported by new telco partnerships.

Control Bionics has secured MHRA registration for its NeuroStrip device, unlocking commercial supply in Great Britain and launching early trials with leading UK institutions.

Acusensus posted a 45% jump in FY26 revenue to $86.2 million, driven by major contract wins in New Zealand and the US, alongside robust domestic expansions. Despite a widened net loss due to a $16 million litigation settlement, adjusted EBITDA climbed 49%, reflecting operational momentum and strategic investments.

Nanoveu’s half-year report reveals a sharp drop in revenue and a widening net loss, offset by key technological milestones including a 16nm AI chip tape-out, drone efficiency gains, and a strategic robotics acquisition.

ResMed Inc. posted a 10% rise in fiscal 2026 revenue to $5.65 billion, bolstered by the acquisition of Noctrix Health and an agreement to sell its MatrixCare business. The company continues to invest in AI-powered digital health solutions amid ongoing patent litigation and a shifting regulatory landscape.

Resmed delivered a strong FY2026 with 10% revenue growth to $5.7 billion, a 17% rise in non-GAAP EPS, and a 10% dividend hike. Strategic moves include selling MatrixCare and acquiring Noctrix Health.

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.